Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Eskouhie Tchaparian
Title The antitumor activity of hyaluronic acid nimuselide-NH2 bioconjugate (CA102N) in human colorectal cancer (CRC)
Journal Cancer Res
Vol 75
Issue 15 Suppl
Abstract Text Cancer Res 2015;75(15 Suppl):Abstract nr 4471


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
CA102N CA 102N|CA-102N|Nim-HA Conjugate|HA-Nimesulide CA102N is composed of sodium hyaluronate (NaHA) in conjugation with the COX-2 inhibitor nimesulide, which may target the HA receptor CD44-expressing tumor cells for growth inhibition (Cancer Res 2015;75(15 Suppl):Abstract nr 4471, PMID: 28392690).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable CA102N Preclinical - Cell line xenograft Actionable In a preclinical study, CA102N inhibited growth of colorectal cancer cell lines in culture, and resulted in rapid tumor shrinkage in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 4471). detail...